Last-Resort drug access for rare tumor patients
NCT ID NCT05041036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides nirogacestat to people with serious desmoid tumors or NOTCH gene mutation tumors who have no other treatment options and cannot join a clinical trial. Each case is reviewed individually by the company, ethics board, and health authorities. The goal is to control the disease when standard treatments have failed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted procedure ease the burden of desmoid tumors?
- New drug ES014 targets desmoid tumors in Mid-Stage trial
- New pill shows promise in slowing rare Cancer's growth
- New pill shows promise for Hard-to-Treat cancers in early trial
- New national registry aims to improve care for rare genetic polyposis syndromes
- New drug trial aims to shrink desmoid tumors